Top Most 36+ What Is Beta 2 Glycoprotein
-
1.Beta-2 Glycoprotein 1 Antibodies
Describes how a beta-2 glycoprotein 1 antibodies test is used to help diagnose antiphospholipid syndrome (APS), determine the cause of an unexplained blood clot, or the cause of recurrent miscarriages in women; when a beta-2 glycoprotein 1 antibodies test is ordered; and what the results of the test might mean
View more » -
2.Beta-2 Glycoprotein 1 Antibodies
Describes how a beta-2 glycoprotein 1 antibodies test is used to help diagnose antiphospholipid syndrome (APS), determine the cause of an unexplained blood clot, or the cause of recurrent miscarriages in women; when a beta-2 glycoprotein 1 antibodies test is ordered; and what the results of the test might mean
View more » -
3.Beta-2 Glycoprotein 1 Antibodies
Describes how a beta-2 glycoprotein 1 antibodies test is used to help diagnose antiphospholipid syndrome (APS), determine the cause of an unexplained blood clot, or the cause of recurrent miscarriages in women; when a beta-2 glycoprotein 1 antibodies test is ordered; and what the results of the test might mean
View more » -
4.Beta-2 Glycoprotein 1 Antibodies
Describes how a beta-2 glycoprotein 1 antibodies test is used to help diagnose antiphospholipid syndrome (APS), determine the cause of an unexplained blood clot, or the cause of recurrent miscarriages in women; when a beta-2 glycoprotein 1 antibodies test is ordered; and what the results of the test might mean
View more » -
5.Beta 2 Glycoprotein I--function In Health And Disease - PubMed
Beta-2 glycoprotein I (beta2GPI) is the principal target of autoantibodies in the antiphospholipid syndrome (APS). It is abundant in human plasma and shares high homology between different mammalian species. Although the exact physiological function of beta2GPI has not been fully elucidated, several …
View more » -
6.Beta-2 Glycoprotein 1 Antibodies, IgG, Serum - Mayo Clinic Laboratories | Neurology Catalog
-
7.Beta-2 Glycoprotein 1 Antibodies, IgG, Serum - Mayo Clinic Laboratories | Neurology Catalog
-
8.Beta-2 Glycoprotein 1 Antibodies, IgG, Serum - Mayo Clinic Laboratories | Neurology Catalog
-
9.Beta-2 Glycoprotein 1 Antibodies, IgG, Serum - Mayo Clinic Laboratories | Neurology Catalog
-
10.B2GMG - Overview: Beta-2 Glycoprotein 1 Antibodies, IgG And IgM, Serum
-
11.B2GMG - Overview: Beta-2 Glycoprotein 1 Antibodies, IgG And IgM, Serum
-
12.B2GMG - Overview: Beta-2 Glycoprotein 1 Antibodies, IgG And IgM, Serum
-
13.Beta-2 Glycoprotein 1 Antibodies, IgG And IgM | ARUP Laboratories Test Directory
Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. Order with Lupus Anticoagulant Reflexive Panel (0030181) and Cardiolipin Antibodies, IgG and IgM (0099344). May also be useful in estimating risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus (SLE). ||Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL) Serum separator tube.
View more » -
14.Beta-2 Glycoprotein 1 Antibodies | Labcorp
-
15.Beta-2 Glycoprotein 1 Antibodies | Labcorp
-
16.Beta-2 Glycoprotein 1 Antibodies | Labcorp
-
17.Beta-2 Glycoprotein 1 Antibodies | Labcorp
-
18.Anti-beta-2-glycoprotein - Glossary | Laboratory, Radiology, Sleep And Genetic | Biron
Anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are antibodies produced by an individual’s immune system against his or her own phospholipids. These phospholipids are found on the surface of the platelets responsible for blood clotting (clot formation). Antibeta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are often responsible (with lupus anticoagulants and anticardiolipins) for abnormal clot formation in veins (phlebitis) and arteries (arterial thrombosis). They are involved in antiphospholipid syndrome, which manifests itself, among other things, by problems during pregnancy (repeated miscarriages in the second or third trimester, preeclampsia), headaches, strokes, chest pain, cognitive changes, epileptic seizures, memory loss, etc.
View more » -
19.Anti-beta-2-glycoprotein - Glossary | Laboratory, Radiology, Sleep And Genetic | Biron
Anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are antibodies produced by an individual’s immune system against his or her own phospholipids. These phospholipids are found on the surface of the platelets responsible for blood clotting (clot formation). Antibeta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are often responsible (with lupus anticoagulants and anticardiolipins) for abnormal clot formation in veins (phlebitis) and arteries (arterial thrombosis). They are involved in antiphospholipid syndrome, which manifests itself, among other things, by problems during pregnancy (repeated miscarriages in the second or third trimester, preeclampsia), headaches, strokes, chest pain, cognitive changes, epileptic seizures, memory loss, etc.
View more » -
20.Anti-beta-2-glycoprotein - Glossary | Laboratory, Radiology, Sleep And Genetic | Biron
Anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are antibodies produced by an individual’s immune system against his or her own phospholipids. These phospholipids are found on the surface of the platelets responsible for blood clotting (clot formation). Antibeta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are often responsible (with lupus anticoagulants and anticardiolipins) for abnormal clot formation in veins (phlebitis) and arteries (arterial thrombosis). They are involved in antiphospholipid syndrome, which manifests itself, among other things, by problems during pregnancy (repeated miscarriages in the second or third trimester, preeclampsia), headaches, strokes, chest pain, cognitive changes, epileptic seizures, memory loss, etc.
View more » -
21.Anti-beta-2-glycoprotein - Glossary | Laboratory, Radiology, Sleep And Genetic | Biron
Anti-beta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are antibodies produced by an individual’s immune system against his or her own phospholipids. These phospholipids are found on the surface of the platelets responsible for blood clotting (clot formation). Antibeta-2-glycoproteins (anti-B2GP1 antibodies, anti-beta-2-glycoprotein antibodies) are often responsible (with lupus anticoagulants and anticardiolipins) for abnormal clot formation in veins (phlebitis) and arteries (arterial thrombosis). They are involved in antiphospholipid syndrome, which manifests itself, among other things, by problems during pregnancy (repeated miscarriages in the second or third trimester, preeclampsia), headaches, strokes, chest pain, cognitive changes, epileptic seizures, memory loss, etc.
View more » -
22.Beta-2 Glycoprotein 1 Antibodies
-
23.Beta-2 Glycoprotein 1 Antibodies
-
24.Beta-2 Glycoprotein 1 Antibodies
-
25.Beta-2 Glycoprotein 1 Antibodies
-
26.Beta-2 Glycoprotein I IgA
-
27.Beta-2 Glycoprotein I IgM
-
28.Frontiers | Immune Complexes Of Beta-2-Glycoprotein I And IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk Of Thrombosis And Early Mortality After Heart Transplantation | Immunology
The presence of anti-Beta 2 glycoprotein antibodies (aB2GP1) of IgA isotype is common in patients with functional impairment of the organs in which B2GP1 is elaborated. Pretransplant IgA aB2GP1 has been associated with increased risk of thrombosis in kidney and heart transplanted patients and has also been related with early mortality after heart transplantation. Circulating immune com¬plexes between IgA and B2GP1 (B2A-CIC) have been described in the blood of patients positive for IgA aB2GP1 with thrombotic clinical symptoms. In kidney transplanted patients, B2A-CIC is a biomarker that predicts which patients IgA aB2GP1 positive are at risk of thrombosis events following kidney transplantation and may lead to early prophylactic treatment. The prevalence of B2A-CIC and its relation with outcomes after heart transplantation is not known. Methods: Follow-up study based on 151 consecutive patients who received a heart transplant. Autoantibodies and B2A-CIC were quantified in pre-transplant serum samples. Three groups of patients were followed-up for two years: Group-1, positive for IgA aB2GP1 and B2A-CIC (N=19). Group-2, only positive for IgA aB2GP1 (N=28). Group-0 (control group): IgA aB2GP1 negative (N=104). Results. Kaplan-Meir survival analysis showed that mortality in B2A-CIC positive was higher than group-0 at 3 months (HR:5.08; 95%CI: 1.36-19.01) and at 2 years (HR:3.82; 95%CI: 1.54-12.66). No significant differences were observed between group-2 and group-0. Multivariate analysis identified B2A-CIC as the most important independent risk factor for early mortality (OR=6.12; 95% CI:1.93-19.4). Post-transplant incidence of thrombosis was significantly higher in B2A-CIC positive patients than in the control group (OR:6.42; 95%CI: 2.1-19.63). Multivariate analysis identified the presence of B2A-CIC (OR:6.13; 95%CI:2.1-19.63) and the pre-transplant habit of smoking actively (OR:4.18; 95%CI:1.35-12.94) as independent risk factor for thrombosis. The proportion of patients who had thrombotic events or died in the first trimester was significantly higher in group-1 (73.7%) than in group-0 (16.3%; p<0.001) and in group-2 (39.3%; p=0.02). Multivariate analysis identified B2A-CIC as the main independent risk factor for early outcomes (mortality or thrombosis) in the first three months after heart transplant (OR=11.42, 95% CI: 1.69-9.68). Conclusion: B2A-CIC are a predictor of early mortality and thrombosis after heart transplant.
View more » -
29.Frontiers | Antiphospholipid Antibodies To Domain I Of Beta-2-Glycoprotein I Show Different Subclass Predominance In Comparison To Antibodies To Whole Beta-2-glycoprotein I | Immunology
Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are a heterogeneous group of autoantibodies raised against circulating blood proteins. Of these proteins, the phospholipid-binding b2-glycoprotein I (b2GPI) is considered to be the main autoantigen in APS. Indeed, IgG antibodies targeting b2GPI (ab2GPI) directly cause both thrombosis and pregnancy morbidity in several mouse models. While antibodies raised against all five domains of b2GPI have been reported, a subgroup of IgG ab2GPI raised against the first domain (DI) of b2GPI (aDI), strongly correlate with thrombotic APS, and drive thrombosis and pregnancy loss in vivo. Few studies have focused on determining the type of IgG subclass(es) for aPL. The subclass of an antibody is important as this dictates the potential activity of an antibody; for example, IgG1 and IgG3 can fix complement better and are able to cross the placenta compared to IgG2 and IgG4. It is unknown what subclass IgG aDI are, and whether they are the same as ab2GPI. To determine IgG subclass distribution for ab2GPI and aDI, we purified total IgG from the serum of 19 APS patients with known ab2GPI and aDI activity. Using subclass-specific conjugated antibodies, we modified our established in-house ab2GPI and aDI ELISAs to individually measure IgG1, IgG2, IgG3 and IgG4. We found that while IgG1, IgG2 and IgG3 ab2GPI levels were similar, a marked difference was seen in IgG subclass aDI levels. Specifically, significantly higher levels of IgG3 aDI were detected compared to IgG1, IgG2, or IgG4 (p<0.05 for all comparisons). Correlation analysis of subclass-specific ab2GPI versus aDI demonstrated that IgG3 showed the weakest correlation (r=0.45, p=0.0023) compared to IgG1 (r=0.61, p=0.0001) and IgG2 (r=0.81, p=0.0001). Importantly, total subclass levels in IgG purified from APS and healthy serum (n=4 per group) did not differ, suggesting that the increased IgG3 aDI signal seen in APS-derived IgG is antigen-specific. To conclude, our data suggests that aDI show a different IgG subclass distribution to ab2GPI. Our results highlight the importance of aDI testing for patient stratification and may point towards differential underlying aPL-driven pathogenic processes that may be subclass restricted.
View more » -
30.Specific Domain V Reduction Of Beta-2-glycoprotein I Induces Protein Flexibility And Alters Pathogenic Antibody Binding - Scientific Reports
Beta-2-glycoprotein I (β2GPI) is a blood protein and the major antigen in the autoimmune disorder antiphospholipid syndrome (APS). β2GPI exists mainly in closed or open conformations and comprises of 11 disulfides distributed across five domains. The terminal Cys288/Cys326 disulfide bond at domain V has been associated with different cysteine redox states. The role of this disulfide bond in conformational dynamics of this protein has not been investigated so far. Here, we report on the enzymatic driven reduction by thioredoxin-1 (recycled by Tris(2-carboxyethyl)phosphine; TCEP) of β2GPI. Specific reduction was demonstrated by Western blot and mass spectrometry analyses confirming majority targeting to the fifth domain of β2GPI. Atomic force microscopy images suggested that reduced β2GPI shows a slightly higher proportion of open conformation and is more flexible compared to the untreated protein as confirmed by modelling studies. We have determined a strong increase in the binding of pathogenic APS autoantibodies to reduced β2GPI as demonstrated by ELISA. Our study is relevant for understanding the effect of β2GPI reduction on the protein structure and its implications for antibody binding in APS patients.
View more » -
31.Significance Of Autoantibodies Against β2-glycoprotein I
Abstract. The antiphospholipid syndrome (APS) is defined by the persistent presence of antiphospholipid antibodies in patients with a history of thrombosis and/
View more » -
32.Posttranslational Forms Of Beta 2-glycoprotein I In The Pathogenesis Of The Antiphospholipid Syndrome - Thrombosis Journal
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (β2GPI) is the major auto antigen in APS. The second was the discovery in more recent years that β2GPI contains allosteric disulphide bonds susceptible to posttranslational modification that may be involved in the development of autoantibodies in APS. The main allosteric disulphide bond in the fifth domain of β2GPI can exist in two redox states: free thiol or oxidised. It is the conformational transformation of β2GPI from its free thiol form to its more immunogenic oxidised form that exposes neo-epitopes on the first and fifth domains. The purpose of this review is to highlight the recent findings on the posttranslational forms of β2GPI in the pathogenesis of APS. We suggest that novel assays quantitating the different redox forms of β2GPI in plasma or serum may be used to supplement existing clinical and laboratory assays to more accurately stratify risk of thrombosis or miscarriage in APS patients.
View more » -
33.Quest Diagnostics: Test Directory
-
34.Beta 2 Glycoprotein 1 | Plasma Product | AROTEC Diagnostics
Autoantibodies directed to negatively charged phospholipids, detected in the serum of patients with SLE & APS. View our range of human antigen.
View more » -
35.RCSB PDB - 6V06: Crystal Structure Of Beta-2 Glycoprotein I Purified From Plasma (pB2GPI)
Crystal structure of Beta-2 glycoprotein I purified from plasma (pB2GPI)
View more » -
36.Anti-Beta-2 Glycoprotein 1 Antibodies, IgG & IgM